Eli Lilly and Company stock may face a short-term decrease of 6.0% and a long-term decrease of 4.9%.
Stock AI’s forecasts:
🔴 -6.0% short-term ⬇️
🔴 -4.9% long-term ⬇️
Stock AI’s (LLY) Forecast get (+6.5% Profit)
StockAI’s analysis delivers real-world results. On 11 April 2024, $LLY ($753.8), StockAI predicted a long-term 🟢 buy signal. It was accurate: 1 month later price increased to $803.1 (🟢6.5%). Buying LLY on this signal yielded a +6.5% profit 💰💰.
LLY-Eli Lilly and Company News
🟢 Eli Lilly and Company settles with medi spa over counterfeit diabetes drug, boosting company reputation and trust in the market.
🔴 Eli Lilly major shareholder sells over $1.6 million worth of stock, potentially signaling lack of confidence in company performance.
🟢 BMO Capital Markets raises price target for LLY stock to $1,001, showing analyst confidence in future growth potential.
🔴 Eli Lilly stock price falls 3.2% on Friday, possibly due to investor concerns over recent shareholder sell-off.
🟢 Zacks Research boosts Q2 2024 earnings per share estimates for Eli Lilly, indicating positive outlook for company’s financial performance.
🔴 Leerink Partnrs lowers Q2 2024 earnings per share estimates for Eli Lilly, leading to potential investor uncertainty about future profitability.
The recent news surrounding Eli Lilly and Company stock has been a mix of positive and negative developments. The settlement agreement with the medi spa over counterfeit drugs is a positive sign for the company’s reputation and trust in the market. However, the major shareholder selling a significant amount of stock may have raised concerns among investors about the company’s performance.
On the other hand, the raise in price target by BMO Capital Markets reflects analyst confidence in Eli Lilly’s future growth potential. Despite this, the stock price fell on Friday, possibly due to investor reactions to the shareholder sell-off. The conflicting estimates from Zacks Research and Leerink Partnrs regarding future earnings further add to the uncertainty surrounding the stock.
Overall, the recent news has created a mixed sentiment among investors, leading to fluctuations in the stock price. It will be important to monitor how these developments continue to impact Eli Lilly and Company’s performance in the coming weeks.
LLY-Eli Lilly and Company Analyst Ratings
### Analyst Ratings for Eli Lilly and Company Stock
📈 Argus raised their price target on Eli Lilly and Company stock from $770.00 to $840.00.
📈 BMO Capital Markets increased their price target on Eli Lilly and Company stock from $900.00 to $1,001.00.
📉 Leerink Partnrs lowered their Q2 2024 earnings per share estimates for Eli Lilly and Company.
### Sources
1. ETF Daily News
2. ETF Daily News
3. ETF Daily News
4. ETF Daily News
5. ETF Daily News
Disclaimer
Investors may consider the AI predictions and news summaries as one factor in their investment decisions alongside their own research and risk tolerance.
Ready to analyze your own portfolio?
Get the same AI-powered insights for any stock you choose. It's easy!
